Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial

作者：Laurie H. Sehn, Kai Hübel, Stefano Luminari, Christian Schölz, Antonio Salar, Shankara Paneesha, Björn Engelbrekt Wahlin, Panayiotis Panayiotidis, Hui‐Peng Lee, Ana Jiménez Ubieto, Juan‐Manuel Sancho, Tae‐Min Kim, Eva Domingo‐Doménech, Takahiro Kumode, Christina Poh, Catherine Thiéblemont, Dries Deeren, Edwin de Wit, Michael Arbushites, Irene Vassallo, Marek Trněný, Björn Engelbrekt Wahlin, Tae Min Kim, Eva Domingo‐Doménech · 发表于：The Lancet · 年份：2025 · DOI：10.1016/s0140-6736(25)01778-7 · 被引用次数：18 · 研究领域：Lymphoma Diagnosis and Treatment、Viral-associated cancers and disorders、Cutaneous lymphoproliferative disorders research